Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation.  This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.

R01 Due Dates: Feb. 5, Jun. 5, Oct. 5

PA-19-077 Expiration Date New Date December 2, 2021 per issuance of NOT-AI-22-009. (Original Expiration Date: January 08, 2022)

Agency Website

Amount Description



      Funding Type





      Medical - Basic Science
      Medical - Translational

      External Deadline

      October 5, 2021